By Hinde Kast (Originally posted at USC Norris Cancer) Cancer can evolve and adapt during therapy, leading to resistance and progression. New non-invasive technologies can…
Category: Research
“Drs. Amir Goldkorn, Timothy Triche, and Vinay Duddalwar awarded a new multi-investigator R01 grant from the National Cancer Institute for translational biomarker studies in advanced…
From CancerNetwork: “Men with metastatic castrate resistant prostate cancer (mCRPC) with undetectable circulating tumor counts (CTCs) were 6.1-fold more likely to have complete response to…
“Amir Goldkorn, MD, of USC Norris Comprehensive Cancer Center, discusses findings from SWOG S1216, which showed that using circulating tumor cell (CTC) count at…
Watch it here: New biomarker may guide initial treatment of metastatic prostate cancer – Keck Medicine of USC (broadcastmed.net) “Prostate cancer is the most common…